Group 1 - The core viewpoint of the article highlights that Guojin Fund recently conducted research on a listed company, Aibo Medical, which has developed an AI digital fitting system called Puno Tong [1] - Guojin Fund was established in 2011 and currently manages a total asset scale of 76.377 billion yuan, ranking 72nd out of 211 in the public fund industry [1] - The fund's non-monetary public fund asset scale is 48.107 billion yuan, ranking 78th out of 211 [1] Group 2 - Guojin Fund manages 63 public funds, ranking 91st out of 211 [1] - The fund has 15 public fund managers, ranking 87th out of 211 [1] - The best-performing public fund product in the past year is Guojin Core Asset One-Year Holding A, with a latest net value of 1.25 and a growth of 52.12% over the past year [1]

Core Viewpoint - Jiutai Fund has recently conducted research on a listed company, Aibo Medical, highlighting its development of the AI digital fitting system, Puno Tong [1] Group 1: Company Overview - Aibo Medical has developed the Puno Tong AI digital fitting system independently [1] - Jiutai Fund participated in Aibo Medical's performance briefing and site visit, as well as the Q3 2025 earnings conference call [1] Group 2: Jiutai Fund Profile - Jiutai Fund was established in 2014, with a total asset management scale of 1.175 billion yuan, ranking 173 out of 211 [1] - The non-monetary public fund asset management scale is 968 million yuan, ranking 151 out of 211 [1] - Jiutai Fund manages 41 public funds, ranking 111 out of 211, with 7 public fund managers, ranking 124 out of 211 [1] - The best-performing public fund product in the past year is Jiutai Quantitative Emerging Industries, with a latest net value of 0.75 and a growth of 41.96% over the past year [1]

Company Overview - Aibo Medical is an innovative ophthalmic medical device manufacturer founded by Dr. Jiang Bing, a high-level talent returning from overseas, and is recognized as a national high-tech enterprise and a national "little giant" enterprise in specialized and innovative sectors [2] - The company offers a comprehensive solution for ophthalmic surgery, myopia prevention, and vision care, with products that fill domestic gaps and break the monopoly of international manufacturers [2] - Aibo Medical leads the artificial lens market in China with the highest market share for a single brand and has pioneered the "full arc non-spherical technology" orthokeratology lens for myopia prevention [2] Event Highlights - The event "Investors Walk into Aibo Medical" was successfully held under the guidance of the Beijing Securities Regulatory Bureau, with over 80 participants including institutional investors, industry analysts, and media representatives [3][4] - Attendees toured the company exhibition hall and observed the production process and quality inspection of artificial lenses, along with demonstrations of the AI fitting system for orthokeratology lenses [3] - Aibo Medical's management shared operational data and discussed challenges faced during development, as well as future innovation plans [4] Industry Insights - The Secretary-General of the Beijing Listed Companies Association emphasized the importance of small and medium-sized listed companies in the capital market and their potential for growth [3] - The association aims to protect investors' rights and facilitate communication between listed companies, investors, and regulatory bodies to enhance market understanding of intrinsic company value [3]

证券代码：688050 证券简称：爱博医疗 公告编号：2025-051 爱博诺德（北京）医疗科技股份有限公司 以简易程序向特定对象发行股票限售股上市流通公告 2025 年 4 月 16 日，爱博诺德（北京）医疗科技股份有限公司（以下简称"爱 博医疗"或"公司"）收到中国证券监督管理委员会（以下简称"中国证监会"） 出具的《关于同意爱博诺德（北京）医疗科技股份有限公司向特定对象发行股票 注册的批复》（证监许可〔2025〕774 号），同意公司以简易程序向特定对象发行股 票（简称"本次发行"）的注册申请。本次发行新增股份 3,593,615 股已于 2025 年 5 月 12 日在中国证券登记结算有限责任公司上海分公司办理完毕股份登记手续。 具体内容详见公司于 2025 年 5 月 14 日在上海证券交易所（以下简称"上交所"） 网站（www.sse.com.cn）披露的《爱博诺德（北京）医疗科技股份有限公司关于 2024 年度以简易程序向特定对象发行股票发行结果暨股本变动的公告》（公告编 号 2025-027）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实 ...

中国银河证券股份有限公司 核查意见 中国银河证券股份有限公司（以下简称"银河证券"或"保荐机构"）作为 爱博诺德（北京）医疗科技股份有限公司（以下简称"爱博医疗"或"公司"） 持续督导机构，根据《中华人民共和国公司法》《中华人民共和国证券法》《证 券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》等有关 法律法规和规范性文件的要求，就爱博医疗以简易程序向特定对象发行股票限售 股上市流通事项进行了审慎核查，具体情况如下： 一、本次上市流通的限售股类型 2025 年 4 月 16 日，爱博医疗收到中国证券监督管理委员会（以下简称"中 国证监会"）出具的《关于同意爱博诺德（北京）医疗科技股份有限公司向特定 对象发行股票注册的批复》（证监许可〔2025〕774 号），同意公司以简易程序 向特定对象发行股票（简称"本次发行"）的注册申请。本次发行新增股份 3,593,615 股已于 2025 年 5 月 12 日在中国证券登记结算有限责任公司上海分公 司办理完毕股份登记手续。 本次上市流通的限售股为公司以简易程序向特定对象发行的限售股份，限售 期为 6 个月，涉及 8 名认购对象，对应限售股数量为 3,5 ...

Core Viewpoint - Aibo Medical's stock has experienced a significant decline in 2023, with a year-to-date drop of 30.17% and a recent 5-day decline of 9.89% [1] Company Overview - Aibo Medical, established on April 21, 2010, and listed on July 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of ophthalmic medical devices [2] - The revenue composition of Aibo Medical includes: 43.86% from artificial lenses, 30.06% from contact lenses, 15.14% from orthokeratology lenses, 6.01% from other myopia control products, 2.37% from other surgical products, 1.62% from other vision care products, and 0.95% from other income [2] - Aibo Medical is categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables, with concepts including ophthalmology, medical devices, medical aesthetics, specialized and innovative, and mid-cap [2] Financial Performance - For the period from January to September 2025, Aibo Medical reported a revenue of 1.144 billion yuan, reflecting a year-on-year growth of 6.43%. However, the net profit attributable to shareholders decreased by 8.64% to 290 million yuan [2] - Since its A-share listing, Aibo Medical has distributed a total of 241 million yuan in dividends, with 173 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Aibo Medical had 17,200 shareholders, an increase of 11.72% from the previous period. The average circulating shares per person decreased by 10.37% to 11,026 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 4.7962 million shares (a decrease of 980,000 shares), and Huabao Zhongzheng Medical ETF, holding 3.8663 million shares (a decrease of 550,000 shares) [3]

Core Viewpoint - Aibo Medical, a leading company in the ophthalmic medical device sector in China, has shown steady growth in revenue and net profit, with significant contributions from its main business segments, including artificial lenses and contact lenses [1][2][6]. Group 1: Business Performance - In Q3 2025, Aibo Medical reported revenue of 1.144 billion yuan, ranking 20th among 50 companies in the industry, with the industry leader, Yingke Medical, generating 7.425 billion yuan [2]. - The company's net profit for the same period was 279 million yuan, placing it 13th in the industry, with the top performer, Lepu Medical, achieving 996 million yuan [2]. - The main business segments include artificial lenses (345 million yuan, 43.86%), contact lenses (236 million yuan, 30.06%), and orthokeratology lenses (119 million yuan, 15.14%) [2]. Group 2: Financial Health - Aibo Medical's debt-to-asset ratio stood at 22.93%, lower than the industry average of 23.66%, indicating strong solvency [3]. - The gross profit margin was 64.80%, despite a decrease from 67.61% in the previous year, still surpassing the industry average of 48.78% [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 11.72% to 17,200, while the average number of circulating A-shares held per shareholder decreased by 10.37% to 11,000 [5]. - Major shareholders include Hong Kong Central Clearing Limited and Huabao Zhongzheng Medical ETF, both of which saw a reduction in their holdings [5]. Group 4: Future Outlook - Citic Securities highlighted Aibo Medical's robust growth in H1 2025, with expectations for continued improvement in Q3, driven by high-value products and new product approvals [6]. - The company is projected to achieve revenues of 1.656 billion, 1.997 billion, and 2.378 billion yuan from 2025 to 2027, with net profits of 428 million, 512 million, and 616 million yuan respectively [6].

Core Viewpoint - Aibo Medical (688050.SH) reported its Q3 2025 results, highlighting significant institutional investor activity and changes in shareholding patterns [1][2] Group 1: Institutional Investor Holdings - As of October 29, 2025, 26 institutional investors disclosed holdings in Aibo Medical A-shares, totaling 49.36 million shares, which represents 25.52% of the total share capital [1] - The top ten institutional investors collectively hold 22.12% of the shares, a decrease of 1.75 percentage points compared to the previous quarter [1] Group 2: Public Fund Holdings - Nine public funds increased their holdings compared to the previous period, with a total increase in holdings of 0.64% [2] - Five public funds reported a decrease in holdings, with a total reduction of 0.39% [2] - Four new public funds disclosed their holdings during this period, while 231 public funds did not disclose their holdings again [2]

Core Viewpoint - Aibo Medical (688050) reported a revenue of 1.144 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 6.43%, while the net profit attributable to shareholders decreased by 8.64% to 290 million yuan [1] Financial Performance - The company's revenue for the first three quarters reached 1.144 billion yuan, marking a 6.43% increase compared to the same period last year [1] - The net profit attributable to shareholders was 290 million yuan, which represents a decline of 8.64% year-on-year [1] Revenue Drivers - The decline in profit is primarily attributed to a decrease in revenue from artificial lenses and contact lenses [1] - The company has increased its investment in promoting its own brand of contact lenses, which has also contributed to the profit decline [1]

Company Performance - Aibo Medical reported Q3 performance with revenue of approximately 1.144 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.43% [1] - The net profit attributable to shareholders was approximately 290 million yuan, showing a year-on-year decrease of 8.64% [1] - Basic earnings per share were 1.51 yuan, down 10.12% year-on-year [1] Market Overview - Aibo Medical's market capitalization is currently 13.6 billion yuan [2] - The A-share market has surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [2]